Colgate-Palmolive Company (CL) Stock Price, News, Analysis

Technical Score (1D)

BUY

News Sentiment

BULLISH

UBS lifted its price target for Colgate‑Palmolive to $106 from $100, signaling confidence in the company’s steady consumer‑staples demand and expected margin improvement. JPMorgan followed suit a few hours later, raising its target to $104 from $96 and maintaining an overweight rating, underscoring expectations of continued growth in the consumer‑staples segment. The simultaneous upgrades suggest that analysts see a near‑term upside of roughly 8–9% for the stock, which could attract buying interest over the next 1–10 trading days. Both upgrades hinge on the company’s ability to sustain margin expansion amid rising raw‑material costs, so any shift in input prices could quickly alter the outlook. The upgrades also reflect optimism that consumer sentiment remains resilient, a factor that will be closely monitored as the company releases its upcoming earnings report. Traders should watch for the earnings announcement, paying particular attention to reported gross margin and advertising spend, which are key drivers of the firm’s profitability. Macro‑economic indicators such as consumer confidence indices and discretionary spending trends will also be important, as they can influence demand for the firm’s products. If the earnings data confirm the expected margin gains, the stock may experience a short‑term rally; conversely, any surprise cost pressure could dampen the bullish sentiment. Therefore, the next few days will be critical for assessing whether the company can deliver the margin improvement that underpins the new price targets.

CL|Company Info

Sector

Consumer Defensive

Industry

Household & Personal Products

Exchange

NYQ

Country

United States

Website

colgatepalmolive.com

Symbol

Description

Colgate-Palmolive is a global consumer goods company focused on two primary segments: Oral, Personal and Home Care, and Pet Nutrition. The company's core business revolves around the manufacturing and distribution of a wide array of well-known brands, including Colgate, Palmolive, and Hill's Science Diet. Its Oral, Personal and Home Care segment offers a diverse portfolio of essential products, from toothpaste and soap to household cleaners, sold through various retail channels, including online platforms. Complementing this, the Pet Nutrition division provides nutritional products for pets, catering to both everyday needs and therapeutic requirements, distributed through pet supply retailers and veterinary professionals. Founded in 1806, Colgate-Palmolive maintains a strong presence in the consumer market, offering established brands and a broad distribution network.

CL|Earnings Snapshot

Earnings Summary

Colgate‑Palmolive is a global consumer‑defensive firm that produces oral, personal and home‑care products and pet nutrition, with well‑known brands such as Colgate and Hill’s. The company operates in the household & personal products industry, where stable consumer demand and pricing power underpin earnings stability. In the last two quarters, Colgate‑Palmolive earned EPS of $0.95 in Q4 2025 and $0.97 in Q1 2026, compared with $0.92 in Q2 2025 and $0.91 in Q3 2025, showing a modest EPS uptick while revenue rose from $5.110 B to $5.131 B in the prior period and then to $5.230 B and $5.324 B in the latest period. The company has beaten analyst estimates in six of the last seven quarters, with EPS exceeding expectations in Q4 2024, Q1 2025, Q2 2025, Q3 2025, Q4 2025, and Q1 2026, reflecting consistent earnings performance. Colgate‑Palmolive has maintained a steady streak of EPS beats and revenue growth, with margins hovering around 60 % and free‑cash‑flow margins robust, supporting a stable earnings outlook. The firm’s ability to deliver above‑estimate earnings has been reinforced by disciplined cost control and a focus on premium product expansion. Analysts have debated margin upside amid rising raw‑material inflation, with Citigroup upgrading the stock to Buy and raising the target to $110, while Piper Sandler and Wells Fargo lifted targets to $96 and $95, citing confidence in margin resilience. The company’s 2030 transformation plan and premium product strategy are highlighted as potential drivers of future margin expansion, though cost pressures remain a concern. Investors should watch for guidance on gross‑margin trends, raw‑material cost inflation, and the execution of the premium strategy in the next earnings release. Key will be the company’s ability to sustain margin expansion while managing cost pressures, as well as any updates on consumer‑spending trends that could influence demand for its core oral‑care and pet‑nutrition lines.

Read full report

EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$0.95	-	-
Q1'26	$0.96	$0.97	+1.4%
Q4'25	$0.94	$0.95	+1.1%
Q3'25	$0.89	$0.91	+2.4%
Q2'25	$0.89	$0.92	+2.8%
Q1'25	$0.86	$0.91	+6.1%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$5.5B	-	-
Q1'26	$5.3B	$5.3B	-0.2%
Q4'25	$5.3B	$5.2B	-0.8%
Q3'25	-	$5.1B	-
Q2'25	-	$5.1B	-
Q1'25	-	$4.9B	-

Full Earnings BreakdownEstimates, actuals, guidance, and historical context

→

Market Data

CL Stock Snapshot

CL is currently trading at $94.38, giving Colgate-Palmolive Company a market cap of 75.38B and a P/E ratio of 36.1. Today's range spans $94.14–$94.44, with shares opening at $94.14 and moving up $0.30 (0.3%) from the prior close. DailyIQ's technical score sits at 95/100 (BUY) with a news sentiment reading of 77/100.

Over the past year CL has traded between $74.55 and $99.33 - the current price is +26.6% off the 52-week low and -5.0% from the high. 32 analysts cover the stock with a Buy consensus and a mean 12-month target of $96.20 (range $80.00–$105.00), implying upside of +1.9%.

CL scores 95/100 (BUY) and is at $94.38 - in the upper portion of its 52-week range within its $74.55–$99.33 annual range. Sentiment at 77/100 is bullish. At 75.38B in Consumer Defensive market cap (P/E: 36.1), this large-cap name benefits from a dynamic that mega-caps don't have: the potential for multiple expansion. When a name at this size with bullish momentum catches the attention of large allocators, the re-rating can be rapid and meaningful.

Earnings revision cycles in large-cap Consumer Defensive names tend to compound: when technicals confirm a BUY thesis (95/100) and news sentiment (77/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $94.38 (in the upper portion of its 52-week range), CL's position within the $74.55–$99.33 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.

News Sentiment Analysis

Sentiment gathered from recent headlines

77/100

Strong NegativeNeutralStrong Positive

BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

UBS lifted its price target for Colgate‑Palmolive (CL) to $106 from $100 while keeping a buy rating. The upgrade reflects confidence in the company's steady consumer staples demand and expected margin improvement. The new target suggests a potential upside of roughly 8% from current levels. Traders should monitor the upcoming earnings release, any changes in raw‑material costs, and consumer sentiment data that could influence CL's valuation.

What did this article say?

UBS analyst Peter Grom has kept a Buy rating on Colgate‑Palmolive (CL). He has lifted the price target from $100 to $106, signaling a more optimistic view. The upgrade reflects confidence in CL's brand strength and steady consumer demand. Investors should watch for CL's next earnings report for further guidance.

What did this article say?

JPMorgan increased its price target for Colgate‑Palmolive (CL) to $104 from $96, maintaining an overweight rating. The upgrade underscores expectations of continued growth in the consumer‑staples segment and margin expansion. The new target implies a potential upside of about 9% from current levels. Traders should watch for the next earnings announcement, any shifts in advertising spend, and macro‑economic indicators affecting discretionary consumer spending.

What did this article say?

Colgate‑Palmolive (CL) is currently in a margin growth debate, with analysts questioning whether the company’s upside potential is already reflected in its stock price. The discussion centers on CL’s pricing power amid rising raw‑material costs and its mandate to sustain higher gross margins. While the firm’s product mix is shifting toward higher‑margin oral‑care lines, cost pressures could dampen the expected margin expansion. Investors should watch how CL’s upcoming earnings address margin guidance and cost‑control measures.

What did this article say?

Colgate‑Palmolive (CL) has posted a 32.4% total return over the past three years, yet valuation tools diverge: a discounted cash flow model indicates upside potential while market multiples already price in optimism. The DCF estimate suggests intrinsic value above current price, implying room for growth if earnings sustain. Market sentiment remains bullish, but investors should watch for any earnings miss that could erode the upside. The company’s strong cash generation and stable dividend support a cautious yet positive outlook.

What did this article say?

Citigroup increased its price target for Colgate-Palmolive to $110 from $105 while keeping a buy rating. The upgrade reflects confidence in the company’s stable earnings and growth prospects. Investors should keep an eye on the next earnings announcement and any guidance updates for further insight.

What did this article say?

Citigroup analyst Filippo Falorni has upgraded Colgate‑Palmolive (CL) to a Buy rating and increased the price target from $105 to $110. The upgrade reflects confidence in the company's steady earnings growth and resilient consumer demand. Traders should monitor CL's upcoming earnings release and any changes in consumer spending trends that could influence the valuation.

What did this article say?

Colgate-Palmolive (CL) has delivered an 11.2% return over the past six months, outperforming the S&P 500’s 8.4% gain. The stock trades at $92.24, reflecting a steady alignment with broader market movements. No significant catalysts or risks were identified in the recent analysis, suggesting a stable outlook. Investors should keep an eye on the upcoming earnings report for potential guidance updates.

What did this article say?

No summary available yet for this article.

What did this article say?

No summary available yet for this article.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

No summary available yet for this article.

What did this article say?

No summary available yet for this article.

CL·Colgate-Palmolive Company

EPS

Revenue

CL Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Discover More

News Sentiment Analysis

Recent News Coverage

Discover More